Skip to main content

Table 2 Subject demographics and baseline characteristics, ITT population

From: Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Characteristic, N = 164

Baseline

Endpoint

Age, mean (SD), years

9.4 (1.9)

-

Sex (%)

  

Boys, n

117 (71.3)

-

Girls, n

47 (28.7)

-

Race, n (%)

  

White

129 (78.7)

-

African American

19 (11.6)

-

Asian

1 (0.6)

-

Native Hawaiian/

Other Pacific Islander

1 (0.6)

-

American Indian/

Alaska Native

1 (0.6)

-

Other

13 (7.9)

-

Weight, mean (SD), lb

75.6 (26.0)

-

Height, mean (SD), in

54.2 (5.2)

-

ADHD-RS-IV Score (SD)

  

Total

14.1 (7.5)

9.9 (7.5)

Inattentive

7.9 (4.3)

6.4 (5.3)

Hyperactive/impulsive

6.2 (4.5)

4.4 (4.5)

AIM-C Child Impact Score (SD)a

62.4 (20.5)

73.4 (18.4)

AIM-C Family Impact Score (SD)a

68.2 (23.3)

78.4 (21.7)

  1. aBased on 161 subjects
  2. ITT = intent to treat; ADHD-RS-IV = ADHD-Rating Scale-IV; AIM-C = ADHD Impact Module-Child